Standard BioTools Inc (NAS:LAB)
$ 2.05 -0.06 (-2.84%) Market Cap: 758.34 Mil Enterprise Value: 387.95 Mil PE Ratio: 0 PB Ratio: 1.35 GF Score: 72/100

Fluidigm Corp at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 06:15PM GMT
Release Date Price: $5.44 (-1.81%)
Edmund Tu
Morgan Stanley, Research Division - Analyst

We have Chris Linthwaite, CEO of Fluidigm, on stage with me today. Vikram Jog, CFO, and Agnes Lee, VP of Investor Relations in the audience.

Before we get started, I just wanted to remind everyone that all disclosures pertaining to this conversation can be found on our disclosure website at www.morganstanley.com\researchdisclosures.

So Chris, very happy to have you here today. I have a series of questions prepared for you, but I think it'd be a good idea to start off with a high-level overview of your company for some of the investors in the room who might not be as familiar.

Stephen Christopher Linthwaite
Fluidigm Corporation - President, CEO & Director

Thank you, again. [Edmund], thank you very much for the invitation and for my extension Morgan Stanley for including Fluidigm in the Healthcare Conference.

I think Fluidigm is a company that's really, really interesting for a number of reasons. First, it's a company that's attacking a $3 billion market, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot